Merck to buy Cidara, maker of a flu prevention drug, for $9.2B

What's new in pharma

November 14, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | Merck to buy Cidara, maker of a flu prevention drug, for $9.2B Merck is looking for its next blockbusters as its top-selling cancer drug Keytruda faces looming generic competition. By Andrew Joseph STAT+ | Next-generation blood thinner from Bristol Myers Squibb, J&J fails key trial The therapy, milvexian, which is being closely watched as potential blockbuster, is being tested in two more late-stage studies. By Allison DeAngelis and Matthew Herper STAT+ | Kura Oncology secures approval for leukemia drug, its first The FDA approved a drug made by Kura Oncology to treat patients with a certain type of genetically altered leukemia. It will be marketed as Komzifti. By Adam Feuerstein Alex Hogan/STAT STAT+ | Up and down the ladder: The latest comings and goings From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry. By Ed Silverman

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser